Development Procurement, Roche(2014-2018)Vice President, CFO Global Product Development, Roche(2010-2013)Date of first appointment : March 20, 2020Term expiration : March 16, 2026EXECUTIVE VICE PRESIDENT / Kun Lo EXECUTIVE VICE PRESIDENTKun LoExecutive Vice President,EPCV Center, Samsung Biologics(2021-Present)Head of DS Center, Samsung Biologics(2020-2021)Head of New Business Division, Samsung Engineering(2013-2020)Date of first appointment : March 17, 2023Term expiration : March 16, 2026EXECUTIVE VICE PRESIDENT / Seung Ho Ryu EXECUTIVE VICE PRESIDENTSeung Ho RyuPresent SAMSUNG BIOLOGICS Business Support Center EVP(2024-Present)SAMSUNG Electronics Business Support Group Leader(Suwon)(2020-2023)Date of first appointment : March 14, 2025Term expiration : March 13, 2028INDEPENDENT DIRECTOR / Eunice Kyonghee Kim Independent DirectorEunice Kyonghee KimWatch the InterviewIndependent Director, Samsung Biologics(2020-Present)Professor, Law School, Ewha Women's University(2010-2021)Vice president, International Association of Korean Lawyers (IAKL)(2008-Present)Deputy-CEO and Chief Legal & Compliance Officer, Hana Financial Group, Inc.(2008-2010)Date of first appointment : March 20, 2020Term expiration : March 16, 2026Independent director / Changwoo Lee Independent DirectorChangwoo LeeIndependent Director, Samsung Biologics(2022-Present)Emeritus Faculty, Business School,Seoul National University(2019-Present)Chairman of the Ethics Committee,Korean Accounting Standard Board(2020-Present)Date of first appointment : March 29, 2022Term expiration : March 13, 2028Independent Director / Seoung Hwan Suh Independent DirectorSeoung Hwan SuhIndependent Director, Samsung Biologics(2024-Present)19th President, Yonsei University(2020-2024)Minister for Ministry of Land, Infrastructure, and Transport(2013-2015)18th Korea Presidential Transition Committee, Committee Member of the Economics Division 2(2013)Date of first appointment : March 15, 2024Term expiration : March 14, 2027Independent Director / Ho Seung Lee Independent DirectorHo Seung LeeIndependent Director, Samsung Biologics(2025-Present)Director of Policy of the presidential Office(2021-2022)Senior Secretary for Economic Affairs of the Presidential Office(2019-2021)First Vice Minister of Strategy and Finance(2018-2019)Date of first appointment : March 14, 2025Term expiration : March 13, 2028Appointment of DirectorsMembers of the board of directors are elected through a resolution of the general meeting of shareholders under the company’s articles of incorporation. Incumbent members may be reelected after the expiration of their terms.Samsung Biologics shall have at least three but no more than ten directors and such directors shall be appointed at the general meeting of shareholders; provided, however, that at least three independent directors shall be appointed and the number of the independent directors shall account for at least a majority of the total number of directors.A resolution for the election of directors shall be adopted by the affirmative votes of a majority of the shareholders present at the meeting, which shall also be at least 1/4 of the total number of issued and outstanding shares.Any vacancy in the office of directors shall be filled at a general meeting of shareholders; provided, however, that if the number of directors does not fall below the number prescribed in Paragraph 1 of Article 29 in the Articles of Incorporation and there is no difficulty in the administration of business, the foregoing shall not be applicable.Term of Office of DirectorThe term of office of directors shall end at the close of the ordinary general meeting of shareholders convened in respect to the last fiscal year within three years from their appointment.ChairpersonThe chairperson of the board of directors shall be appointed among the directors by a resolution of the board of directors.Resolution of the BODThe resolution of the board of directors shall be adopted in

Development- And others Communication Communicate to - Client- Staff- Regulatory Agency- Audit committee- Others BCMO The strategic teams,which focuses on strategic issues that impact the organization's core objectives, products and services, are led by top management.The crisis management team has primary responsibility for addressing any crisis impacting the organization.※ BCMO: Business Continuity Management Office The tactical teams,which manage and coordinate the continuity of the processes required to deliver the impacted products and services and ensure that the resources are allocated appropriately, are led by a team leader. Tactical level plans provide a framework to coordinate strategic goals and decisions with the operational response teams. The operational teams,which focus on the continuity of the activities that contribute to the processes that deliver the prioritized products and services, is led by each functional site matter expert. An operational response establishes the necessary capability required to continue delivering priotised products and services. The strategic teams,which focuses on strategic issues that impact the organization's core objectives, products and services, are led by top management.The crisis management team has primary responsibility for addressing any crisis impacting the organization.※ BCMO: Business Continuity Management Office The tactical teams,which manage and coordinate the continuity of the processes required to deliver the impacted products and services and ensure that the resources are allocated appropriately, are led by a team leader. Tactical level plans provide a framework to coordinate strategic goals and decisions with the operational response teams. The operational teams,which focus on the continuity of the activities that contribute to the processes that deliver the prioritized products and services, is led by each functional site matter expert. An operational response establishes the necessary capability required to continue delivering priotised products and services. Annual Operation Embedding BCMS is the ongoing cycle of activities of the business continuity management program, which builds organizational resilience, and is the professional practice that defines how to integrate business continuity awareness and practice into business as usual activities. Embedding BCMS Analysis - Reviews and assesses an organization to identify our objectives, how it functions and the constrains of its operating environment · Look into environment to find unidentified risks in terms of location, supply chain society, politics and so on.· Internal/external stakeholders· Business Impact Analysis for product, process, activity Design - Identifies and selects appropriate solutions to determine how continuity can be achieved in the event of an incident · Performing Risk and Threat Mitigation Measures Implementation - Implements the solutions agreed in the designed stage · Development of Tactical/Operational Business Continuity Strategy· Establishment of Business Continuity Plans & a response structure Validation - Confirms that the business continuity program meets the objectives set in the policy and the plans and procedures in place are effective. · Exercise Program: performing annual exercises with various types of scenario by each department as well as company-wide· Management Review to ensure it aligns with organizational objectives Analysis - Reviews and assesses an organization to identify our objectives, how it functions and the constrains of its operating environment · Look into environment to find unidentified risks in terms of location, supply chain society, politics and so on.· Internal/external stakeholders· Business Impact Analysis for product, process, activity Design - Identifies and selects appropriate solutions to determine how continuity can be achieved in the event of an incident · Pe

developments warrant a refined perspective on our outlook, we will engage with the market in a timely and transparent manner. Amid ongoing signals of potential tariff actions on pharmaceuticals by the U.S. administration, we are closely monitoring prospective policy shifts and associated risks. We acknowledge the possible ramifications for our clients and ultimately, for patients, and will be working closely with our clients to develop countermeasures that can be implemented swiftly and effectively. We remain committed to delivering reliable and sustainable results grounded in our resilient business model and robust operational capabilities.Demonstration of Global CDMO Leadership through Strong Order Intake and Proven Client Satisfaction Global Competitiveness Underpinned by Enduring Client Trust and Operational Excellence Building on our commitment to exceptional quality and client-centric execution, we continue to solidify our market leadership by achieving significant business milestones. In January, we entered into a landmark CMO agreement valued at approximately USD 1.4 billion (KRW 2 trillion) with a leading European pharmaceutical company - marking the largest single order in our history, accounting for nearly 40% of our total annual order volume for 2024. Since then, we have been actively engaged in discussions with both existing and prospective clients for additional orders, further reinforcing our growth trajectory. Our CDO business also continues to advance steadily, supported by ongoing advancement of our platform technologies and service capabilities. While sustaining stable collaborations with existing partners, we are broadening our client portfolio, thereby strengthening our position as a fully integrated CDMO through enhanced synergy between our CMO and CDO operations. We are honored to have once again been recognized with the CDMO Leadership Awards by Outsourced Pharma, marking our twelfth consecutive year of distinction. This year, we were named a winner in the "Biologics- Global" category and additionally received the "Best Facility" award, affirming the strength of our manufacturing infrastructure, uncompromising quality standards, and technological expertise. Selected based on direct feedback from global biopharmaceutical clients, this award underscores the trust we have built through consistently delivering high-quality biomedicines and fostering long-term partnerships grounded in reliability and performance. We will continue to strive for excellence by delivering exceptional value to our clients and further strengthening our leadership as a trusted global CDMO.Laying the Groundwork for Future Growth with Sustained Investment and Execution Excellence Strengthening Sustainable Global Leadership through a Three-Pillar Growth Strategy Our antibody-drug conjugate (ADC) facility commenced operations in the first quarter and is running smoothly in line with our plans. By integrating this new capability with our existing antibody manufacturing infrastructure, we are now better positioned to offer more comprehensive solutions to global clients engaged in ADC therapeutics. The construction of our fill & finish line is also progressing as scheduled. This April, we initiated operations at Plant 5, designed to elevate efficiency and operational stability through advanced automation and digital transformation. As part of our broader digital transformation initiatives, we implemented and internalized a state-of-the-art Manufacturing Execution System (MES) within Plant 5, replacing previously manual workflows with a more advanced digital manufacturing infrastructure. Also, we implemented various advanced automated systems to enhance operational efficiency and workplace safety. These enhancements are expected to boost productivity and quality, supporting long-term profitability. Looking ahead, we will focus on ensuring a stable and timely ramp-up of Plant 5, supported by favorable contract discussion

CEO MESSAGE Driven. For Life.AnnouncementDear valued investors and shareholders, This is John Rim from Samsung Biologics. To begin, I would like to extend my heartfelt appreciation for your continued interest and steadfast support of our business.Key Highlights2024 Financial Performance• Posted KRW 4.5T in consolidated revenue (YoY +23%) -Consolidated: Rev. 4,547B, OP. 1,320B (OPM: 29.0%) - Biologics: Rev. 3,497B, OP. 1,321B (OPM: 37.8%) - Bioepis: Rev. 1,538B, OP. 435B (OPM: 28.3%)• Consolidated revenue to grow +20-25% in 2025CDMOSecured 17 of the global top 20 big pharma clients *14 clients in 2023• Exceeded KRW 5T in contract volume *Signed 3 major contracts worth KRW 1T+• Launched 4 new CDO platforms *S-TensifyTM, S-AfuCHOTM, S-OptiChargeTM, S-HiconTM• Surpassed 300 regulatory manufacturing approvals *340 approvals in totalBusiness Expansion• Completion of ADC facility construction• P5 at Biocampus II to be operational in Apr. '25• Investment in PFS Mother-line (CGMP ready by Oct. 27) *Foundational set-up for future global expansion• Continued investments via Life Science Fund *Flagship Pioneening, BrickBio, Latus Bio, Generate BiomedicinesBiosimilar• SB17 (bStelara): EU launch & US FDA approval * Launched in EU, including Germany, Spain, France and the Netherlands• SB15 (bEylea):EC & US FDA approval• SB12 (bSoliris) :US FDA approval• SB16 (bProlia):Positive CHMP opinion *EMA's Committee for Medicinal Products for Human UseToday, Samsung Biologics announced our financial results for the fourth quarter and full year of 2024.Fiscal year 2024 was marked by a global economic slowdown and heightened geopolitical tensions. Despite these challenging environments, Samsung Biologics achieved robust performance through customer-centric services and operational excellence.Most notably, we achieved a transformative milestone by becoming the first company within the Korean biopharmaceutical industry to surpass KRW 4.5 trillion in annual revenue. This unprecedented financial performance, setting a new company record with an impressive 23% year-over-year growth, underscores our cutting-edge expertise, distinctive competencies, and the unwavering confidence our clients place in us, thereby reaffirming our market leadership and global competitiveness.As we embark on 2025, we are proud to announce that we have achieved a record-breaking order worth KRW 2 trillion on January 14th, the highest contract volume in our company's history. This remarkable accomplishment not only reinforces our market leadership but also fuels our continued growth momentum, and we remain dedicated to excellence in customer satisfaction by supporting the reliable supply of critical medicines to patients around the world without any delay.Looking ahead to 2025, we foresee an even more robust financial trajectory, propelled by the successful ramp-up of our Plant 4 coupled with the continued full utilization of Plants 1 through 3. Building on this momentum, we have established an annual revenue growth target of 20~25%, positioning us to surpass KRW 5 trillion mark in consolidated revenue within just 14 years of our founding. We take pride in sharing this positive outlook with our esteemed investors, reaffirming our unwavering commitment to driving sustainable growth, broadening our global presence, and optimizing shareholder value.Sustained and Stable Growth of CDMO Business Record-Breaking Contract Wins, Driven by Exceptional Capabilities and Client TrustWe reached an unprecedented milestone in 2024, surpassing KRW 5 trillion in annual contract wins, collaborating with a number of global pharmaceutical giants across the US, Asia, and Europe. This extraordinary achievement was highlighted by a succession of groundbreaking contracts that underscore our prominence in the global pharmaceutical landscape: a KRW 1.45 trillion agreement with a US-based pharmaceutical company in July, followed by a KRW 1.7 trillion contract with an Asian pharmaceutical company in October. Als

developmentBiosimilar• SB17 (bStelara): Launched in Europe and Korea*15 countries incl. Germany, Spain and Netherlands• SB12 (bSoliris): Approved by US FDA• SB15 (bEylea): Received positive CHMP Opinion*Committee for Medicinal products for Human Use (CHMP) of EMAToday, Samsung Biologics announced our financial results for the third-quarter of 2024.For the first time in the company's history, and the first in the domestic biopharmaceutical industry, Samsung Biologics exceeded KRW 3 trillion in cumulative consolidated revenue by the third quarter. Separate revenues of Samsung Biologics and Bioepis posted growth rates of 21% and 26% year-over-year, respectively, while consolidated revenue grew by 15% year-over-year to KRW 1.2 trillion, with operating profit of KRW 339 billion. With this outstanding accomplishment, we went one step closer to achieving an annual consolidated revenue of KRW 4 trillion for the first time in the history of Korean biopharmaceutical industry.In light of this solid growth momentum, we have raised our annual revenue guidance from 10~15% year-over-year growth to 15~20%. This great feat - raising our guidance for two consecutive years stems from our proactive investment activities to address market demands in a timely manner, our strong competitive edge in speed and execution capability, and solid foundation of our CDMO business, all of which have been maximized through our unique Operational Excellence initiatives.Continuous Growth of CDMO Business Contract Wins Continue, Leveraging Robust CompetitivenessOur CDMO business continued to progress smoothly as always. Contract negotiations with Global Pharma clients, based on strategic partnership, remain ongoing.We achieved a record-setting USD 3.3 billion in total cumulative orders for this year. We pride ourselves on our robust capabilities and strategic foresight, which have solidified our position as a trusted partner within the global pharmaceutical landscape. We finalized a monumental contract worth KRW 1.7 trillion with a pharmaceutical company based in Asia yesterday, marking the largest deal disclosed in our company's history. We have also succeeded in securing one of the top 20 global pharmaceutical companies as our clients, bringing the total number of the top 20 clients to 17. And having already secured partnerships with 17 of the top 20 global pharmaceutical companies, we are now strategically positioning ourselves to further expand our client base across key regions, with an extended focus on the Japanese market. Our recent participation at BIO Japan underscored our commitment to fostering deeper relationships with local clients, recognizing the critical importance of proximity in facilitating collaboration and trust. As we aim to extend our reach to the top 40 global pharmaceutical companies as our clients, we fully understand that cultivating close, enduring partnerships with our Japanese counterparts will be pivotal in driving sustained growth and innovation. By leveraging our proven expertise, we are poised to meet the evolving needs of the biopharmaceutical industry and create lasting value for our clients.Meanwhile, we are advancing our CDO business by bolstering our capabilities in delivering tailored solutions and cutting-edge technology platforms. This quarter, we unveiled S-AfuCHOTM, a platform that enables the production of antibodies with enhanced Antibody-dependent Cellular Cytotoxicity (ADCC), and S-OptiChargeTM, a platform that precisely modulates protein charge variants. More recently, we launched S-HiConTM, a high-concentration formulation platform developed to proactively address the growing market demand for the high-dose biopharmaceuticals.This year, we have launched four new platforms, further elevating our global competitiveness by swiftly and adeptly addressing diverse needs of clients under our new CDO business slogan, 'Agile, Flexible, Focused on You'.Moreover, our company recently attained over 300 global regulatory appr